Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2566)

POSTPONEMENT OF RE-ELECTION OF THE BOARD

The term of office of the first session of the Board of Directors (the "**Board**") of Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (杭州九源基因生物醫藥股份有限公司) (the "**Company**") will expire on November 20, 2026. As the preparation for the re-election of the new session of the Board is still in progress, in order to ensure the continuity and stability of the relevant work of the Board, the re-election of the Board will be postponed. Concurrently, the terms of office of the respective specialized committees of the Board and the senior management of the Company will also be extended correspondingly until a new session of the Board is approved by the shareholders of the Company at a general meeting in accordance with the articles of association of the Company (the "**Articles of Association**").

Prior to the completion of the re-election of the new session of the Board, the first session of the Board, the members of the respective specialized committees of the Board and the senior management of the Company will continue to perform their corresponding duties and obligations in accordance with the relevant laws and regulations, the Articles of Association and other relevant provisions.

The postponement of the re-election of the Board will not affect the normal operation of the Company. The Company will actively advance the relevant work to complete the re-election of the Board as soon as practicable, and will fulfill its information disclosure obligations in a timely manner.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, November 19, 2026

As of the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀), Dr. Zhou Demin (周德敏) and Dr. Huang Wenli (黃文禮) as independent non-executive directors; and (iv) Mr. Xu Feihu (徐飛虎) as an employee representative director.